stockportfolio.pro
Alnylam Pharmaceuticals, Inc. (ALNY)
Healthcare · Biotechnology · NasdaqGS
Alnylam Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.16M | $89.91M | $74.91M | $219.75M | $492.85M | $844.29M | $1.04B | $1.83B | $2.25B | $3.71B |
| Gross profit | — | — | $73.11M | $194.69M | $418.67M | $729.28M | $868.60M | $1.52B | $1.92B | $3.03B |
| Net income | $-410.11M | $-490.87M | $-761.50M | $-886.12M | $-858.28M | $-852.82M | $-1.13B | $-440.24M | $-278.16M | $313.75M |
| Net margin | -869.6% | -545.9% | -1016.6% | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
Source: Alnylam Pharmaceuticals, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into ALNY stock?
At today's market cap of $38.90B, Alnylam Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 27.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $465.38M from the FY ending 2025-12-31). For comparison, revenue 49.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Alnylam Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ALNY in your portfolio →
Alnylam Pharmaceuticals, Inc. financial history by metric
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals, Inc. — frequently asked questions
What is Alnylam Pharmaceuticals, Inc.'s revenue?
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $3.71B for fiscal year 2025, up 65.2% from the prior year, according to its SEC filings.
Is Alnylam Pharmaceuticals, Inc. profitable?
Yes. ALNY earned net income of $313.75M in fiscal 2025, a net margin of 8.4%.
What is ALNY's P/E ratio?
Alnylam Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 73.0 based on the latest data in our nightly-refreshed cache.
How fast is Alnylam Pharmaceuticals, Inc. growing?
ALNY's revenue grew at roughly 49.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Alnylam Pharmaceuticals, Inc. have?
As of fiscal year 2025, ALNY carried roughly $1.01B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Alnylam Pharmaceuticals, Inc.'s gross margin?
ALNY's gross margin was 81.6% in fiscal 2025 — gross profit of $3.03B on revenue of $3.71B.
What is Alnylam Pharmaceuticals, Inc.'s market cap?
Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalization of about $38.90B, based on the latest data in our nightly-refreshed cache.
When does Alnylam Pharmaceuticals, Inc.'s fiscal year end?
ALNY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ALNY stock?
At today's market cap of $38.90B, Alnylam Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 27.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $465.38M from the FY ending 2025-12-31). For comparison, revenue 49.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Alnylam Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.